Chief Executive Officer Brian Sullivan outlined the company’s clinical and commercial priorities for its lead asset, ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — Hong Kong, Shanghai & Florham Park, NJ ...

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...